Last reviewed · How we verify
NCT03781635: KETABIS
Comparison of BIS Index Variations: Bolus Versus Infusion Ketamine, and Impact on the Anesthesia Gas Consumption
Phase 4 trial testing bolus of intravenous ketamine in Bolus Versus Infusion Ketamine, Anesthesia Gas Consumption in 50 participants. Completed in 30 September 2019.
29 March 2019
Quick facts
| Lead sponsor | Ciusss de L'Est de l'Île de Montréal |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 25 September 2018 |
| Primary completion | 29 March 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- bolus of intravenous ketamine — full drug profile →
- continuous infusion of intravenous ketamine — full drug profile →
Conditions studied
- Bolus Versus Infusion Ketamine, Anesthesia Gas Consumption — all drugs for Bolus Versus Infusion Ketamine, Anesthesia Gas Consumption →
Sponsor
Ciusss de L'Est de l'Île de Montréal — full company profile →
Who can join
18 and older, any sex, with Bolus Versus Infusion Ketamine, Anesthesia Gas Consumption. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the present study is to show that i.v. ketamine boluses might lead to significant and clinically relevant BIS index increase that might lead to an increase in anesthesia dosing (halogenous gas) when compared to an i.v. continuous infusion of ketamine without any bolus.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The impact of bolus versus continuous infusion of intravenous ketamine on bispectral index variations and desflurane administration during major surgery: The KETABIS study.
Carrara L, Nault M, Morisson L, Godin N, et al · · 2021 · cited 15× · PMID 34474441 · DOI 10.1097/eja.0000000000001588
Verify or expand the search:
- PubMed search for NCT03781635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ciusss de L'Est de l'Île de Montréal trials
Trials by the same sponsor.
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT06500143 — Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery · completed
- NCT06522698 — Optimizing Research Data Acquisition With Smart Pill Bottles · NA · not yet recruiting
- NCT06522711 — Virtual Reality for Anxiolysis and Pharmacological Sparing · NA · not yet recruiting
- NCT07112261 — Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03781635 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ciusss de L'Est de l'Île de Montréal
- Last refreshed: 4 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03781635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing